ANALPRAM HC SUMMARY
Analpram HC® Cream is a topical preparation containing hydrocortisone acetate 1% or 2.5% w/w and pramoxine hydrochloride 1% w/w in a hydrophilic cream base containing stearic acid, cetyl alcohol, Aquaphor *, isopropyl palmitate, polyoxyl 40 stearate, propylene glycol, potassium sorbate, sorbic acid, triethanolamine lauryl sulfate, and purified water.
Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Published Studies Related to Analpram HC (Hydrocortisone / Pramoxine)
Comparative trial of moisturizer containing licochalcone A vs. hydrocortisone lotion in the treatment of childhood atopic dermatitis: a pilot study. [2011.06]
CONCLUSION: The effectiveness of LA lotion is equal to that of HC lotion. It was suggested that moisturizer containing LA could be used both for treatment of acute and maintenance phase in mild-to-moderate childhood AD. (c) 2010 The Authors. Journal of the European Academy of Dermatology and Venereology (c) 2010 European Academy of Dermatology and Venereology.
Comparative trial of moisturizer containing licochalcone A vs. hydrocortisone lotion in the treatment of childhood atopic dermatitis: a pilot study. [2010.09.14]
Background Although moisturizer usage has been considered a mainstay of treatment for atopic dermatitis (AD) patients, few clinical studies have been investigated... It was suggested that moisturizer containing LA could be used both for treatment of acute and maintenance phase in mild-to-moderate childhood AD.
Biological and hemodynamic effects of low doses of fludrocortisone and hydrocortisone, alone or in combination, in healthy volunteers with hypoaldosteronism. [2010.08]
Low doses of hydrocortisone (HC) and fludrocortisone (FC) administered together improve the prognosis after septic shock; however, there continues to be disagreement about the utility of FC for this indication. The biological and hemodynamic effects of HC (50 mg intravenously) and FC (50 microg orally) were assessed in 12 healthy male volunteers with saline-induced hypoaldosteronism in a placebo-controlled, randomized, double-blind, crossover study performed according to a 2 x 2 factorial design...
A pilot study comparing hydrocortisone premedication to concomitant azathioprine treatment in preventing loss of response to infliximab. [2009.09]
OBJECTIVES: Antibodies to infliximab may lead to loss of response to infliximab (IFX) in Crohn's disease. Azathioprine (AZA) coadministration prevents the formation, whereas hydrocortisone (HC) premedication reduces the levels of antibodies to IFX. This pilot study aims at assessing the efficacy of these strategies to prevent loss of response to IFX... CONCLUSION: This prospective 2-year pilot study has not confirmed superiority of any available strategy to maintain the efficacy of IFX.
Modified-release hydrocortisone to provide circadian cortisol profiles. [2009.05]
CONTEXT: Cortisol has a distinct circadian rhythm regulated by the brain's central pacemaker. Loss of this rhythm is associated with metabolic abnormalities, fatigue, and poor quality of life. Conventional glucocorticoid replacement cannot replicate this rhythm. OBJECTIVES: Our objectives were to define key variables of physiological cortisol rhythm, and by pharmacokinetic modeling test whether modified-release hydrocortisone (MR-HC) can provide circadian cortisol profiles. SETTING: The study was performed at a Clinical Research Facility... CONCLUSION: By defining circadian rhythms and using modern formulation technology, it is possible to allow a more physiological circadian replacement of cortisol.
Clinical Trials Related to Analpram HC (Hydrocortisone / Pramoxine)
Pharmacokinetics of Hydrocortisone After Subcutaneous Administration in Chronic Adrenal Insufficiency [Not yet recruiting]
Patients with chronic adrenal insufficiency need to adapt their hydrocortisone replacement
dose in conditions of physical or psychological stress to prevent life threatening adrenal
crisis. In cases of more severe impairment or unsecure gastrointestinal absorption (e. g.
gastroenteritis, severe infectious disease), parenteral administration of the hydrocortisone
dose is crucial. The study is conducted to offer patients the possibility to perform
hydrocortisone self administration in emergency situations in a way of administration which
is easy to perform and accepted by the patient. Therefore, pharmacokinetics and safety of
subcutaneous hydrocortisone administration will be studied and compared to intramuscular
Sensitivity of Short and Long Allele Carriers of the 5-HTTLPR to Environmental Threat Post Hydrocortisone Administration [Recruiting]
The current study will test the causal relationship between elevated levels of cortisol and
the serotonin transporter gene (5-HTTLPR) as these factors influence sensitivity to
environmental threat. The investigators predict that carriers of the short allele of the
serotonin transporter gene who have elevated cortisol levels will be most sensitive to
threatening environments, whereas carriers of the long allele who do not have elevated
cortisol (placebo subjects) will be least sensitive.
Hydrocortisone Replacement in Patients With Secondary Adrenal Insufficiency (SUPREME CORT) [Recruiting]
The aim of this study is to investigate whether a physiologically low hydrocortisone (HC)
dose is better for cognition as compared to a physiologically high HC dose. In addition,
quality of life, metabolic profile and somatosensation will be described in relation to HC
Prevention of Posttraumatic Stress Disorder (PTSD) With Early Hydrocortisone Treatment: Pilot [Recruiting]
People experience a wide range of outcomes following a traumatic event. Although rates
differ depending on type of trauma, 20-60% of trauma victims may develop posttraumatic
stress disorder (PTSD). However, not all trauma victims develop PTSD. Previous research
has found that trauma victims who develop PTSD excrete lower levels of urinary cortisol
immediately after a trauma than victims who do not develop PTSD. Other research has
suggested that increasing levels of cortisol may protect against the development of PTSD in
patients such as yourself- but this has not yet been examined. Cortisol is a naturally
occurring hormone in your body, and the present study is designed to test whether increasing
cortisol levels can protect against or decrease symptoms of PTSD. Participants in this
study will be randomly assigned to one of two treatment groups. Participants will receive
either hydrocortisone (20mg, twice per day) or a placebo (a sugar pill) for 10 days with a
six-day taper. There is an equal chance of being in either treatment group, and neither the
participant nor the experimenters will know which treatment was received (except in case of
Hair Cortisol and Testosterone Levels in Patients With and Without Acute Myocardial Infarction(MI) [Recruiting]
The purpose of this study is to determine whether hair levels of cortisol and testosterone
are elevated in patients with acute MI compared to controls.